Related Experiment Video
Updated: Oct 2, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Choices in medical management for prevention of acute ischemic stroke
1Department of Neurology, Indiana University School of Medicine, 541 Clinical Drive, CL 365, Indianapolis, IN 46202, USA. jdfleck@iupui.edu
Insights
Preventing ischemic stroke is crucial. This review covers medical therapies, including four antiplatelet agents (aspirin, aspirin plus dipyridamole, clopidogrel, ticlopidine) and warfarin, for secondary stroke prevention.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Stroke remains a primary cause of mortality and long-term disability globally.
- Effective secondary prevention strategies are vital for reducing stroke recurrence and associated burdens.
Purpose of the Study:
- To review the efficacy of medical therapies for the secondary prevention of ischemic stroke.
- To compare and contrast available antiplatelet agents and discuss the role of warfarin.
Main Methods:
- Literature review of studies on antiplatelet agents and warfarin for stroke prevention.
- Analysis of clinical trial data regarding the efficacy, similarities, and differences of these medications.
Main Results:
- Four primary antiplatelet agents (aspirin, aspirin plus dipyridamole, clopidogrel, ticlopidine) have demonstrated efficacy in preventing ischemic stroke.
- Warfarin's use in secondary stroke prevention is also considered.
Conclusions:
- Medical management, particularly with antiplatelet agents, plays a significant role in the secondary prevention of ischemic stroke.
- Understanding the nuances of these therapies is essential for optimal patient care and risk reduction.
Abstract:
Stroke is a leading cause of death and disability. Although advances are being made in the treatment of acute ischemic stroke, its prevention is equally as important. Identification and management of risk factors are essential. Medical therapy is also helpful in the secondary prevention of ischemic stroke. There are currently four platelet-antiaggregating agents used to prevent ischemic stroke: aspirin, aspirin plus dipyridamole, clopidogrel, and ticlopidine. The relevant studies proving their efficacy are noted, as are some of their similarities and differences. The use of warfarin is also discussed.
Related Concept Videos
Atherosclerosis III: Management
Acute Coronary Syndrome IV: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Ischemic Stroke l: Introduction
Angina IV: Management
Atherosclerosis IV: Nursing Management